Top 11 CRISPR Stocks to Invest In

7. Editas Medicine, Inc. (NASDAQ:EDIT)

Number of Hedge Fund Holders: 23

Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology company developing gene-editing therapies using CRISPR technology to treat genetic disorders by modifying patients’ genomes. The company’s lead candidate, EDIT-301, is in late-stage clinical trials for sickle cell disease (SCD) and beta-thalassemia.

On December 12, Editas Medicine, Inc. (NASDAQ:EDIT) announced a strategic pivot to focus on its in vivo CRISPR gene-editing programs, driven by promising preclinical results. The company aims to extend its cash runway into Q2 2027 and plans to demonstrate human proof of concept for its in vivo treatments within the next two years. Editas Medicine, Inc. (NASDAQ:EDIT) sees its in vivo gene-editing platform as a game-changer, with the potential to unlock new therapeutic possibilities and solidify its leadership in the field.

Significant updates on clinical development are not expected in the near term, with the next major insights anticipated in early 2025. At that time, the company is expected to outline additional potential indications for its CRISPR technology. Meanwhile, Editas has reported promising preclinical results in gene editing of hematopoietic stem cells (HSCs), showing potential for treating both sickle cell disease and beta-thalassemia.